Impact of circadian rhythmicity and sleep restriction on circulating endocannabinoid (eCB) N-arachidonoylethanolamine (anandamide)
Randomised controlled trialHumans
- Design
- Randomised controlled trial
- Subjects
- 14 young adults
- Dose used in the study
- No palmitoylethanolamide was given; serum levels were measured
- Duration
- Two nights of normal (8.5 h) or restricted (4.5 h) sleep in each condition, separated by at least one month, followed by 24-hour blood sampling
- What was measured
- Serum anandamide, oleoylethanolamide and palmitoylethanolamide across 24 hours with identical meals, after normal and restricted sleep.
What the authors reported
This trial found:
- Mean 24-hour anandamide was 0.697 plus or minus 0.11 pmol/ml with a biphasic profile peaking at 0200 and 1500 and lowest at 1000.
- Oleoylethanolamide and palmitoylethanolamide followed the same pattern.
- None of the three was changed by sleep restriction at any time of day, unlike 2-AG in earlier work.
Limits of this study
A small randomised crossover measurement study; no PEA was given. Results describe endogenous rhythms in healthy young adults only. The author reports no conflicts of interest.
Source
PubMed 31610409 · doi:10.1016/j.psyneuen.2019.104471
Entry checked against the abstract on PubMed on 2026-09-22. The dose shown is the dose the researchers used. It is not a recommendation. How to read this page.